Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ophthalmoplegia Clear all
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Not yet recruiting No phase listed Observational

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

NCT07240805
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD), Lewy Body Disease
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Lutherville, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Young Plasma Transfusions for Progressive Supranuclear Palsy

NCT02460731
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Fresh Frozen Plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Active, not recruiting No phase listed Observational

Automated Imaging Differentiation of Parkinsonism

NCT05913687
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
Interventions
AIDP
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

NCT01537549
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
alpha-lipoic acid and L-acetyl carnitine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 1 Interventional

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

NCT02658916
View directory record Official record
Conditions
Supranuclear Palsy, Progressive
Interventions
BIIB092
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Active, not recruiting Not applicable Interventional

Art Therapy in Progressive Supranuclear Palsy

NCT06588673
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Art Thrapy
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]APN-1607 as a PET Biomarker

NCT05005819
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Healthy Volunteers
Interventions
[18F] APN-1607
Drug
Lead sponsor
Invicro
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426
View directory record Official record
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752, Placebo
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
41 Years to 81 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Cognitive Impairement In Frontotemporal Dementia

NCT03452956
View directory record Official record
Conditions
Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
Interventions
None-Observation Only
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
997 participants
Timeline
2003 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Capsular Tension Rings in Intraocular Lens Rotation

NCT04436198
View directory record Official record
Conditions
Cataract, Ophthalmoplegia, Ophthalmologic Complication
Interventions
MORCHER® EYEJET® CTR Types 14, 14A, and 14C, Toric IOL Only
Device
Lead sponsor
Rachel Lieberman
Federal
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

NCT03076671
View directory record Official record
Conditions
Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions
Palliative Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 105 Years
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed Phase 2 Interventional

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

NCT04734379
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Syndrome
Interventions
Fasudil
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
View directory record Official record
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

NCT04014387
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Human CNS Tau Kinetics in Tauopathies

NCT03545126
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD MAPT Mutation)
Interventions
13C6 Leucine
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 10, 2026, 4:40 PM EDT
Active, not recruiting No phase listed Observational

A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes

NCT05956834
View directory record Official record
Conditions
PSP, CBD, Progressive Supranuclear Palsy, FTD, Corticobasal Degeneration, Frontotemporal Dementia, Frontotemporal Lobar Degeneration
Interventions
PAMSys, LEGSys
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed Phase 1Phase 2 Interventional

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

NCT04253132
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Tolfenamic Acid, Placebos
Drug
Lead sponsor
NeuroTau, Inc.
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

NCT02132052
View directory record Official record
Conditions
Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy

NCT00005903
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
GDNF & Synchro Med Infusion System
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

NCT02494024
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Single dose C2N-8E12, Single dose placebo
Drug
Lead sponsor
C2N Diagnostics
Industry
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 10, 2026, 4:40 PM EDT